BN Business News
Add your company to Business Communicator →

Business · 17/11/20261 min read

Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

Extended Phase 3 INDIGO follow-up results, including data from patients who crossed over to VORANIGO® (vorasidenib) from placebo, were presented as an oral presentation on November 14 Exploratory INDIGO analysis providing insight into VORANIGO's impact on seizure control and quality of...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →